Search research articles
Contact Us
Filters
Showing results (391-400 of 488) with videos related to
Page
of 49
Sort By:
Oncotarget
|
February 5, 2011
Phase 2 clinical trial of 5-azacitidine, valproic acid, and all-trans retinoic acid in patients with high-risk acute myeloid leukemia or myelodysplastic syndrome
Emmanuel Raffoux, Audrey Cras, Christian Recher, et al.
Nature Medicine
|
November 6, 2007
Extralymphatic virus sanctuaries as a consequence of potent T-cell activation
Mike Recher, Karl S Lang, Alexander Navarini, et al.
British Journal of Haematology
|
June 19, 2013
Tumour lysis syndrome and acute kidney injury in high-risk haematology patients in the rasburicase era. A prospective multicentre study from the Groupe de Recherche en Réanimation Respiratoire et Onco-Hématologique
Michael Darmon, François Vincent, Laurent Camous, et al.
Blood
|
July 10, 2014
Core-binding factor acute myeloid leukemia in first relapse: a retrospective study from the French AML Intergroup
Marie-Anne Hospital, Thomas Prebet, Sarah Bertoli, et al.
Haematologica
|
February 26, 2015
Dasatinib in high-risk core binding factor acute myeloid leukemia in first complete remission: a French Acute Myeloid Leukemia Intergroup trial
Nicolas Boissel, Aline Renneville, Thibaut Leguay, et al.
Blood
|
May 31, 2011
Dismal prognostic value of monosomal karyotype in elderly patients with acute myeloid leukemia: a GOELAMS study of 186 patients with unfavorable cytogenetic abnormalities
Aurore Perrot, Isabelle Luquet, Arnaud Pigneux, et al.
Leukemia
|
August 22, 2014
Early death in acute promyelocytic leukemia (APL) in French centers: a multicenter study in 399 patients
R Rahmé, X Thomas, C Recher, et al.
Leukemia
|
January 17, 2013
A phase Ib GOELAMS study of the mTOR inhibitor RAD001 in association with chemotherapy for AML patients in first relapse
S Park, N Chapuis, F Saint Marcoux, et al.
Blood Cancer Journal
|
May 31, 2022
Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib
Alexander E Perl, Naoko Hosono, Pau Montesinos, et al.
European Journal of Haematology
|
January 26, 2017
Impact of body-surface area on patients' outcome in younger adults with acute myeloid leukemia
Xavier Cahu, Martin Carré, Christian Recher, et al.
Page
of 49
Search research articles
Search
Showing results (391-400 of 488) with videos related to
Sort By:
Page
of 49
Oncotarget
|
February 5, 2011
Phase 2 clinical trial of 5-azacitidine, valproic acid, and all-trans retinoic acid in patients with high-risk acute myeloid leukemia or myelodysplastic syndrome
Emmanuel Raffoux, Audrey Cras, Christian Recher, et al.
Nature Medicine
|
November 6, 2007
Extralymphatic virus sanctuaries as a consequence of potent T-cell activation
Mike Recher, Karl S Lang, Alexander Navarini, et al.
British Journal of Haematology
|
June 19, 2013
Tumour lysis syndrome and acute kidney injury in high-risk haematology patients in the rasburicase era. A prospective multicentre study from the Groupe de Recherche en Réanimation Respiratoire et Onco-Hématologique
Michael Darmon, François Vincent, Laurent Camous, et al.
Blood
|
July 10, 2014
Core-binding factor acute myeloid leukemia in first relapse: a retrospective study from the French AML Intergroup
Marie-Anne Hospital, Thomas Prebet, Sarah Bertoli, et al.
Haematologica
|
February 26, 2015
Dasatinib in high-risk core binding factor acute myeloid leukemia in first complete remission: a French Acute Myeloid Leukemia Intergroup trial
Nicolas Boissel, Aline Renneville, Thibaut Leguay, et al.
Blood
|
May 31, 2011
Dismal prognostic value of monosomal karyotype in elderly patients with acute myeloid leukemia: a GOELAMS study of 186 patients with unfavorable cytogenetic abnormalities
Aurore Perrot, Isabelle Luquet, Arnaud Pigneux, et al.
Leukemia
|
August 22, 2014
Early death in acute promyelocytic leukemia (APL) in French centers: a multicenter study in 399 patients
R Rahmé, X Thomas, C Recher, et al.
Leukemia
|
January 17, 2013
A phase Ib GOELAMS study of the mTOR inhibitor RAD001 in association with chemotherapy for AML patients in first relapse
S Park, N Chapuis, F Saint Marcoux, et al.
Blood Cancer Journal
|
May 31, 2022
Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib
Alexander E Perl, Naoko Hosono, Pau Montesinos, et al.
European Journal of Haematology
|
January 26, 2017
Impact of body-surface area on patients' outcome in younger adults with acute myeloid leukemia
Xavier Cahu, Martin Carré, Christian Recher, et al.
Page
of 49